Menotropins

The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.

Regulatory status

Menotropins is an approved prescription medicine in one or more of the United States, United Kingdom and European Union. When listed by the vendors in this index it is labeled for laboratory research use only, and nothing here is medical advice or an endorsement of human use.

The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.

PepIndex records the size and shape of the published research footprint only. It does not evaluate or summarise clinical significance, does not describe administration, and nothing here is a claim of safety or efficacy.

• Retrospective analysis: The application of human menopausal gonadotropin combined with letrozole for IUI in patients undergoing artificial insemination by husband due to unexplained or mild male factors — Frontiers in endocrinology (2022)

  Peer-reviewed article indexed in PubMed, published in Frontiers in endocrinology (2022).

• Human menopausal gonadotropin (HMG) combined different doses of letrozole for treating anovulatory infertility in patients with polycystic ovary syndrome: a randomized controlled trial — Journal of assisted reproduction and genetics (2025)

  Peer-reviewed article indexed in PubMed, published in Journal of assisted reproduction and genetics (2025).

• Pulsatile GnRH or human chorionic gonadotropin/human menopausal gonadotropin as effective treatment for men with hypogonadotropic hypogonadism: a review of 42 cases — European journal of endocrinology (1998)

  Peer-reviewed article indexed in PubMed, published in European journal of endocrinology (1998).

• Highly Purified Human Menopausal Gonadotropin (Menopur(®)): A Profile of Its Use in Infertility — Clinical drug investigation (2018)

  Peer-reviewed article indexed in PubMed, published in Clinical drug investigation (2018).

• Subcutaneous human menopausal gonadotropin administration for controlled ovarian hyperstimulation with intrauterine insemination cycles — American journal of obstetrics and gynecology (2000)

  Peer-reviewed article indexed in PubMed, published in American journal of obstetrics and gynecology (2000).

• Implantation, abortion, and birth after in vitro fertilization using the natural menstrual cycle or follicular stimulation with clomiphene citrate and human menopausal gonadotropin — Journal of in vitro fertilization and embryo transfer : IVF (1985)

  Peer-reviewed article indexed in PubMed, published in Journal of in vitro fertilization and embryo transfer : IVF (1985).

PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.

No certificate records are indexed. Either none are published, or those published could not be read without an account.

How to read a certificate of analysis